TeamDrive
RUS

Doctor Ryadom

www.drclinics.ru

Doctor Ryadom is a dynamically developed network of private clinics which was created in Moscow in 2014 by Team Drive and a group of private investors within public-private partnership with Moscow City Government. 

The first clinic started its work in April 2014 in a new, densely populous district in South-East of Moscow. 

In less than a year Doctor Ryadom opened in such areas of Moscow 10 modern, well-equipped, multidimensional clinics for adults and children. All clinics offer free reception of public using mandatory health insurance policy when patients with voluntary health insurance and on a fee basis are also serviced.  A wide range of modern technologies are fixed in the network of clinics Doctor Ryadom which are based on personalized medicine.

The project is actively developing: the company is planning to improve and expand the network of clinics and create clinical and diagnostic centers.

You can read all the details on Doctor Ruyadom website.

Media Center

  • 17 August 2018

    Researchers developed a new class of drugs to reduce cardiovascular risk

    Researchers from Cleveland Clinic (Cleveland, Ohio, USA) have designed a potential new class of drugs that may reduce cardiovascular risk by targeting a specific microbial pathway in the gut.

  • 16 August 2018

    The Pulse of Biopharma M&A

    M&A-driven dealmaking in 2018 across the biopharmaceutical industry is on track to becoming the second highest of the decade. “There’s been a significant increase in private financing, principally driven by Series A financing, which tells us that new company formation has accelerated in the last four to five years,” says Neel Patel, managing director, commercial strategy and planning, at Syneos Health Consulting, and co-author of theNeel Patel 2018 Dealmakers’ Intention Study. 

  • 15 August 2018

    What Issues Are Top of Mind for Smaller Biotech and Emerging Biopharma Companies?

    As a small biotech company proceeds from startup phase through rapid growth of its operations, it will face many critical decisions along the way. Indeed, many of the decisions will be pivotal to determining whether the company will successfully move from a small incubator of ideas to the ability to shepherd a R&D asset through its pipeline to achieving commercial success. This article will provide readers with selected examples of such decisions, plus questions or factors to be considered when making decisions that will have significant impact on the future of their growing firm. 

  • 14 August 2018

    FPI conducts preclinical trials of drug intended to save seriously injured

    Human trials of the drug being developed to save the seriously injured and to extend the “golden hour” – the time regarded as the most critical for saving lives – can begin at least in three years, according to Anatoly Kovtun, Head of the project group of the Foundation for Advanced Research Projects (FPI).

Read more